X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES AJANTA PHARMA SUVEN LIFESCIENCES/
AJANTA PHARMA
 
P/E (TTM) x 21.1 21.8 96.8% View Chart
P/BV x 4.1 3.8 109.8% View Chart
Dividend Yield % 0.6 0.9 59.0%  

Financials

 SUVEN LIFESCIENCES   AJANTA PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
AJANTA PHARMA
Mar-19
SUVEN LIFESCIENCES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2511,422 17.6%   
Low Rs155898 17.3%   
Sales per share (Unadj.) Rs49.1233.5 21.0%  
Earnings per share (Unadj.) Rs9.744.0 22.1%  
Cash flow per share (Unadj.) Rs11.452.2 21.8%  
Dividends per share (Unadj.) Rs1.509.00 16.7%  
Dividend yield (eoy) %0.70.8 95.3%  
Book value per share (Unadj.) Rs60.3255.1 23.6%  
Shares outstanding (eoy) m127.2888.02 144.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.15.0 83.2%   
Avg P/E ratio x20.926.4 79.2%  
P/CF ratio (eoy) x17.822.2 80.1%  
Price / Book Value ratio x3.44.5 74.0%  
Dividend payout %15.420.5 75.4%   
Avg Mkt Cap Rs m25,825102,081 25.3%   
No. of employees `0001.16.8 15.8%   
Total wages/salary Rs m6134,307 14.2%   
Avg. sales/employee Rs Th5,832.63,022.6 193.0%   
Avg. wages/employee Rs Th571.5633.4 90.2%   
Avg. net profit/employee Rs Th1,153.8569.1 202.7%   
INCOME DATA
Net Sales Rs m6,25320,554 30.4%  
Other income Rs m233211 110.4%   
Total revenues Rs m6,48520,765 31.2%   
Gross profit Rs m1,9825,664 35.0%  
Depreciation Rs m213721 29.6%   
Interest Rs m4612 399.1%   
Profit before tax Rs m1,9555,143 38.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,273 56.4%   
Profit after tax Rs m1,2373,870 32.0%  
Gross profit margin %31.727.6 115.0%  
Effective tax rate %36.724.8 148.4%   
Net profit margin %19.818.8 105.1%  
BALANCE SHEET DATA
Current assets Rs m5,62211,812 47.6%   
Current liabilities Rs m1,1683,776 30.9%   
Net working cap to sales %71.239.1 182.2%  
Current ratio x4.83.1 153.9%  
Inventory Days Days8177 105.2%  
Debtors Days Days3682 44.0%  
Net fixed assets Rs m3,32514,398 23.1%   
Share capital Rs m127175 72.6%   
"Free" reserves Rs m7,54722,277 33.9%   
Net worth Rs m7,67422,452 34.2%   
Long term debt Rs m147 210.6%   
Total assets Rs m9,13526,962 33.9%  
Interest coverage x43.2444.3 9.7%   
Debt to equity ratio x00 616.2%  
Sales to assets ratio x0.70.8 89.8%   
Return on assets %14.014.4 97.6%  
Return on equity %16.117.2 93.5%  
Return on capital %26.023.0 113.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,06610,682 47.4%   
Fx outflow Rs m2,0012,102 95.2%   
Net fx Rs m3,0658,580 35.7%   
CASH FLOW
From Operations Rs m6993,748 18.7%  
From Investments Rs m-6-2,228 0.3%  
From Financial Activity Rs m-577-1,475 39.1%  
Net Cashflow Rs m11645 257.3%  

Share Holding

Indian Promoters % 63.4 73.8 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.6 -  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.0 214.7%  
Shareholders   37,287 20,968 177.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat, Crude Oil Continues Momentum, and Top Cues in Focus Today(Pre-Open)

India share markets ended marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 71 points (down 0.2%) and the NSE Nifty closed down by 24 points (down 0.2%).

Related Views on News

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jun 24, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS